Search

Your search keyword '"Jean-Michel Dorey"' showing total 28 results
Start Over Author "Jean-Michel Dorey" Topic 0302 clinical medicine
28 results on '"Jean-Michel Dorey"'

1. Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort

Author

Christophe Lançon, Baptiste Pignon, T Korchia, Guillaume Fond, Damien Etchecopar-Etchart, Raphaëlle Richieri, Christine Passerieux, Jasmina Mallet, David Misdrahi, Delphine Capdevielle, Mélanie Faugere, Mathieu Urbach, F. Schürhoff, N Coulon, Bruno Aouizerate, Romain Rey, Ophélia Godin, L. Boyer, Julien Dubreucq, P.L. Sunhary de Verville, Isabelle Chereau, Jean-Michel Dorey, Marion Leboyer, Julie Clauss-Kobayashi, Caroline Dubertret, Fabrice Berna, P.-M. Llorca, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Fondation FondaMental [Créteil], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Les Hôpitaux Universitaires de Strasbourg (HUS), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre hospitalier Charles Perrens [Bordeaux], Nutrition et Neurobiologie intégrée (NutriNeuro), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Centre Référent de Réhabilitation Psychosociale [CH Alpes Isère], Centre Hospitalier Alpes Isère, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier le Vinatier [Bron], Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Hospitalier de Versailles André Mignot (CHV), FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group: P M Llorca, C Lançon, L Boyer, Imagerie MOléculaire pour applications THéranostiques personnalisées (IMOTHEP), Institut FRESNEL (FRESNEL), Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Male, Quality of life, medicine.medical_specialty, Inflammation, Overweight, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Humans, ComputingMilieux_MISCELLANEOUS, Biological Psychiatry, Pharmacology, Psychiatry, business.industry, Patient Acuity, medicine.disease, Physical activity level, 3. Good health, 030227 psychiatry, Peripheral, C-Reactive Protein, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Cohort, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], medicine.symptom, business, Inflammatory biomarker, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Biomarkers
Abstract

International audience; Background: Peripheral inflammation is associated with impaired prognosis in schizophrenia (SZ). Highly sensitive C-reactive protein (hs-CRP) is the most used inflammatory biomarker in daily practice. However, no consensual cut-off has been determined to date to discriminate patients with peripheral inflammation from those without.Aims: To determine if patients with peripheral inflammation between 1 and 3 mg/L had poorer outcomes compared to those with undetectable CRP ( 1 mg/L is a reliable marker to detect peripheral inflammation in patients with schizophrenia.

Published
2021

2. Impact of Cognitive, Functional, Behavioral Disorders, and Caregiver Burden on the Risk of Nursing Home Placement

Author

Marine Dufournet, Virginie Dauphinot, Claire Moutet, Mathieu Verdurand, Floriane Delphin-Combe, Pierre Krolak-Salmon, Florian Delphin-Combe, Zaza Makaroff, Denis Federico, Marie-Hélène Coste, Isabelle Rouch, Jean-Michel Dorey, Alexis Lepetit, Keren Danaila, Julien Vernaudon, Anthony Bathsavanis, Alain Sarciron, Yves Guilhermet, Sylvain Gaujard, Pierre Grosmaître, Centre Mémoire de Ressources et de Recherche Lyon (CMRR), Hospices Civils de Lyon (HCL)-Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Mémoire de Ressources et de Recherche [Lyon] (CMRR), MEMORA group: Pierre Krolak-Salmon, Virginie Dauphinot, Florian Delphin-Combe, Zaza Makaroff, Denis Federico, Marie-Hélène Coste, Isabelle Rouch, Jean-Michel Dorey, Alexis Lepetit, Keren Danaila, Julien Vernaudon, Anthony Bathsavanis, Alain Sarciron, Yves Guilhermet, Sylvain Gaujard, Pierre Grosmaître, Claire Moutet, Mathieu Verdurand, CCSD, Accord Elsevier, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, medicine.medical_specialty, Longitudinal study, Activities of daily living, [SDV]Life Sciences [q-bio], Psychological intervention, neurocognitive disorders, functional limitations, Risk Assessment, Nursing home placement, 03 medical and health sciences, Patient Admission, 0302 clinical medicine, Cost of Illness, medicine, Humans, Dementia, Cognitive Dysfunction, Apathy, Longitudinal Studies, 030212 general & internal medicine, Psychiatry, General Nursing, Aged, Aged, 80 and over, caregiver burden, business.industry, Health Policy, General Medicine, Caregiver burden, medicine.disease, Nursing Homes, 3. Good health, [SDV] Life Sciences [q-bio], Caregivers, Attention Deficit and Disruptive Behavior Disorders, Attributable risk, Anxiety, Female, neuropsychiatric symptoms, France, Geriatrics and Gerontology, medicine.symptom, business, 030217 neurology & neurosurgery, dementia
Abstract

Objectives To estimate the attributable fraction of nursing home placement associated with cognitive impairment, neuropsychiatric symptoms, behavioral disorders, functional limitations, and caregiver burden. Design Longitudinal study conducted on the “MEMORA cohort” linked with both regional public health insurance and hospital discharge databases. Setting Memory center at the University Hospital of Lyon, France. Participants A sample of 2456 outpatients attending the memory center between 2012 and 2017. Measures Cognitive impairment, functional limitations, neuropsychiatric symptoms/behavioral disorders, and caregiver burden were measured with the Mini-Mental State Examination, the Instrumental Activities of Daily Living scale, the Neuropsychiatric Inventory (NPI), and a short version of the Zarit Burden Inventory, respectively. Sociodemographics characteristics were collected during the first visit. Comorbidities were gathered from the hospital discharge database. Dates of nursing home placement were obtained from the public health insurance database. Results More than 38% of nursing home placements were attributable to caregiver burden, and the attributable fraction associated with functional limitations exceeded 35%. Between 20% and 25% of nursing home placements were due to cognitive impairment whereas less than 16% were attributable to neuropsychiatric symptoms or behavioral disorders. The associations between anxiety or agitation and nursing home placement were mediated by caregiver burden. Apathy or aberrant motor behaviors were associated with a higher risk of nursing home placement independently of caregiver burden. Conclusions/Implications Our findings suggest that a high proportion of nursing home placements are attributable to caregiver burden and functional limitations in outpatients attending a memory center. Cognitive impairment and neuropsychiatric symptoms or behavioral disorders contribute less to nursing home placements. Interventions directed to delay nursing home placement should emphasize actions toward reducing caregiver burden and functional limitations of patients.

Published
2019

3. Mental Health of People with Dementia During COVID-19 Pandemic: What Have We Learned from the First Wave?

Author

Anne-Lise Bohec, Romain Bachelet, Jean-Michel Dorey, Céline Borg, Jean Claude Getenet, Isabelle Rouch, Mathieu Herrmann, Bernard Laurent, Romain Rey, Elodie Pongan, Laboratoire de Psychologie et NeuroCognition (LPNC ), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Université de Lyon, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier le Vinatier [Bron]

Subjects
Gerontology, Male, Coronavirus disease 2019 (COVID-19), Population, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, Pandemic, Lockdown, medicine, Dementia, Humans, 030212 general & internal medicine, education, Depression (differential diagnoses), Aged, education.field_of_study, General Neuroscience, COVID-19, General Medicine, Middle Aged, medicine.disease, Mental health, 3. Good health, Psychiatry and Mental health, Clinical Psychology, Cross-Sectional Studies, Caregivers, Communicable Disease Control, Anxiety, Residence, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, Geriatrics and Gerontology, medicine.symptom, Psychology, Alzheimer’s disease, 030217 neurology & neurosurgery
Abstract

International audience; BACKGROUND: People with dementia (PWD) and their caregivers are populations highly vulnerable to COVID-19 pandemic and its consequences. A better knowledge of the living conditions during the first lockdown is necessary to prevent the risk of poor mental health (PMH) in this population. OBJECTIVE: The present study aimed to compare the mental health of caregivers of PWD living at home or in nursing-homes and to identify specific factors influencing their mental health. METHODS: We conducted an anonymous cross-sectional online survey in France from March 17 to May 11, 2020. Three hundred and eighty-nine caregivers accompanying a PWD living at home (HC) and 159 accompanying a PWD living in a nursing home (NHC) participated in the study. Caregivers' mental health including anxiety, depression, stress, and burden was assessed with self-reported standardized scales. RESULTS: Half of the caregivers exhibited PMH, including depression, anxiety, or self-reported stress. Similar PMH rates were provided whatever the PWD place of residence. Regarding HC, our results also highlighted a number of risk factors for PMH, including the fact that caregiver live with PWD, to give increased support to PWD, and to feel more isolated for managing PWD since lockdown. CONCLUSION: PMH was observed for caregivers of PWD during lockdown, whatever PWD living place, suggesting that concern for PWD may explain more of caregiver distress than increased material tasks. In the future, it will be necessary to pay attention to caregivers after the crisis by estimating the longer-term impact on their mental health.

Published
2021

4. Le syndrome sérotoninergique : une revue actualisée de la littérature

Author

T. d’Amato, M. Nourredine, Benjamin Rolland, Jean-Michel Dorey, Bruno Mégarbane, and L. Jurek

Subjects
medicine.medical_specialty, business.industry, Gastroenterology, Cognition, Therapeutic education, Serotonergic, 030226 pharmacology & pharmacy, Serotonin syndrome, 03 medical and health sciences, 0302 clinical medicine, Clinical heterogeneity, Internal Medicine, medicine, Drug adverse effect, medicine.symptom, business, Intensive care medicine, 030217 neurology & neurosurgery, Pharmacogenetics
Abstract

The serotonin syndrome is a potentially deadly complication resulting from drug adverse effect, drug-drug interaction or overdose involving one or more serotonergic molecules, e.g., antidepressants, psychostimulants and sometimes an "ignored" serotonergic compound. The serotonin syndrome typically consists of a clinical triad including cognitive/behavioral, neurovegetative and neuromuscular features. However, this syndrome is characterized by major clinical heterogeneity, making the diagnosis difficult in practice. Moreover, many practitioners are quite unaware of this syndrome. Available scores and classifications can help physicians in their diagnosis approach. Knowing the responsible molecules, their potential interactions and mechanisms of action can help preventing this complication allowing therapeutic education among patients. This updated article reviews the clinical presentation, prevention, management, and pathophysiology of the serotonin syndrome, and addresses the most recent advances in pharmacogenetics regarding this syndrome.

Published
2019

5. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)

Author

Ophelia Godin, Guillaume Fond, Ewa Bulzacka, Frank Schürhoff, Laurent Boyer, Andre Myrtille, Meja Andrianarisoa, Bruno Aouizerate, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau, Jean-Michel Dorey, Caroline Dubertret, Julien Dubreucq, Catherine Faget, Christophe Lancon, Sylvain Leignier, Jasmina Mallet, David Misdrahi, Christine Passerieux, Romain Rey, Paul Roux, Pierre Vidailhet, Dominique Costagliola, Marion Leboyer, Pierre-Michel Llorca, Méja Andrianarisoa, Olivier Blanc, Lore Brunel, Isabelle Chéreau-Boudet, Gabrielle Chesnoy-Servanin, Jean-Marie Danion, Thierry D'Amato, Arnaud Deloge, Claire Delorme, Hélène Denizot, Cécile Fluttaz, Sandrine Fonteneau, Franck Gabayet, Elisabeth Giraud-Baro, Marie-Christine Hardy-Baylé, Delphine Lacelle, Christophe Lançon, Hakim Laouamri, Tifenn Le Gloahec, Yann Le Strat, Emeline Metairie, Pauline Peri, Sylvie Pires, Céline Portalier, Céline Roman, Mathilde Sebilleau, Aurélie Schandrin, Priscille Schneider, Franck Schurhoff, Arnaud Tessier, Anne-Marie Tronche, Mathieu Urbach, Florence Vaillant, Aurélie Vehier, Estelle Vilà, Hanan Yazbek, Anna Zinetti-Bertschy, CCSD, Accord Elsevier, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Fondation FondaMental [Créteil], Sorbonne Université (SU), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), IMRB - 'Neuropsychiatrie translationnelle' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital de la Colombière, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre hospitalier Charles Perrens [Bordeaux], Nutrition et Neurobiologie intégrée (NutriNeuro), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1 (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), CHU Clermont-Ferrand, Université d'Auvergne - Clermont-Ferrand I (UdA), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Référent de Réhabilitation Psychosociale [CH Alpes Isère], Centre Hospitalier Alpes Isère, Assistance Publique - Hôpitaux de Marseille (APHM), Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier de Versailles André Mignot (CHV), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group: Méja Andrianarisoa 16 , Bruno Aouizerate 17 , Fabrice Berna 18 , Olivier Blanc 19 , Lore Brunel 16 , Ewa Bulzacka 16 , Delphine Capdevielle 20 , Isabelle Chéreau-Boudet 19 , Gabrielle Chesnoy-Servanin 21 , Jean-Marie Danion 18 , Thierry D'Amato 21 , Arnaud Deloge 22 , Claire Delorme 23 , Hélène Denizot 19 , Jean-Michel Dorey 21 , Caroline Dubertret 24 , Julien Dubreucq 23 , Catherine Faget 25 , Cécile Fluttaz 23 , Guillaume Fond 16 , Sandrine Fonteneau 26 , Franck Gabayet 23 , Elisabeth Giraud-Baro 23 , Marie-Christine Hardy-Baylé 26 , Delphine Lacelle 19 , Christophe Lançon 25 , Hakim Laouamri 27 , Marion Leboyer 16 , Tifenn Le Gloahec 16 , Yann Le Strat 24 , Pierre-Michel Llorca 19 , Jasmina Mallet 28 , Emeline Metairie 25 , David Misdrahi 22 , Christine Passerieux 26 , Pauline Peri 25 , Sylvie Pires 19 , Céline Portalier 24 , Romain Rey 21 , Céline Roman 23 , Mathilde Sebilleau 26 , Aurélie Schandrin 20 , Priscille Schneider 18 , Franck Schurhoff 16 , Arnaud Tessier 22 , Anne-Marie Tronche 19 , Mathieu Urbach 26 , Florence Vaillant 25 , Aurélie Vehier 21 , Pierre Vidailhet 18 , Estelle Vilà 22 , Hanan Yazbek 20 , Anna Zinetti-Bertschy 18, Centre de Psychiatrie et Neurosciences (U894), Université Montpellier 1 - UFR de Médecine (UM1 Médecine), Université Montpellier 1 (UM1), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Laboratoire de sciences cognitives et psycholinguistique (LSCP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Hôpital Charles Perrens, Centres d'addictologies - Région Centre, Physiopathologie clinique et expérimentale de la schizophrénie, Université Louis Pasteur - Strasbourg I-IFR37-Institut National de la Santé et de la Recherche Médicale (INSERM), Vulnérabilité à la schizophrénie : des bases neurobiologiques à la thérapeutique, Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier de Bayeux, Psychiatrie, Centre Hospitalier le Vinatier [Bron], Centre Hospitalier de Saint-Egrève (CH Ste-Egrève), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Laboratoire de neuropsychologie cognitive et prise en charge des troubles de la communication schizophrénique, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Hôpital Mignot, Université Paris Diderot - Paris 7 (UPD7), Service de pédiatrie multidisciplinaire [Hôpital de la Timone Enfants - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE), Neuropsychiatrie : recherche épidémiologique et clinique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université Panthéon-Sorbonne - UFR Histoire (UP1 UFR09), Université Panthéon-Sorbonne (UP1), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital Civil de Strasbourg, Dynamique des capacités humaines et des conduites de santé (EPSYLON), Université Montpellier 1 (UM1)-Université Paul-Valéry - Montpellier 3 (UM3)-Université de Montpellier (UM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg-Université de Strasbourg (UNISTRA)

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Comorbidity, Neuropsychological Tests, Medication Adherence, Machine Learning, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Cognition, Outpatients, medicine, Humans, Cognitive Dysfunction, Stage (cooking), Medical prescription, Major depressive episode, Biological Psychiatry, Pharmacology, Depressive Disorder, Major, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, Neuropsychology, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, medicine.disease, Prognosis, 030227 psychiatry, 3. Good health, Mood, Clinical staging, Schizophrenia, Cognitive remediation therapy, Cohort, Polypharmacy, Female, Schizophrenic Psychology, France, medicine.symptom, business, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Algorithms
Abstract

International audience; Objective: Existing staging models have not been fully validated. Thus, after classifying patients with schizophrenia according to the staging model proposed by McGorry et al. (2010), we explored the validity of this staging model and its stability after one-year of follow-up.Method: Using unsupervised machine-learning algorithm, we classified 770 outpatients into 5 clinical stages, the highest being the most severe. Analyses of (co)variance were performed to compare each stage in regard to socio-demographics factors, clinical characteristics, co-morbidities, ongoing treatment and neuropsychological profiles.Results: The precision of clinical staging can be improved by sub-dividing intermediate stages (II and III). Clinical validators of class IV include the presence of concomitant major depressive episode (42.6% in stage IV versus 3.4% in stage IIa), more severe cognitive profile, lower adherence to medication and prescription of >3 psychotropic medications. Follow-up at one-year showed good stability of each stage.Conclusion: Clinical staging in schizophrenia could be improved by adding clinical elements such as mood symptoms and cognition to severity, relapses and global functioning. In terms of therapeutic strategies, attention needs to be paid on the factors associated with the more stages of schizophrenia such as treatment of comorbid depression, reduction of the number of concomitant psychotropic medications, improvement of treatment adherence, and prescription of cognitive remediation.

Published
2018

6. Attention in schizophrenia: Impaired inhibitory control, faulty attentional resources, or both?

Author

Romain Rey, George A. Michael, Jean-Michel Dorey, Delphine Fabre, Sophie Brunet, Thierry d'Amato, Catherine Padovan, Laboratoire d'Etude des Mécanismes Cognitifs (EMC), Université Lumière - Lyon 2 (UL2), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CCSD, Accord Elsevier, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Male, Adolescent, Process (engineering), Schizophrenia (object-oriented programming), [SDV]Life Sciences [q-bio], behavioral disciplines and activities, Task (project management), 03 medical and health sciences, Young Adult, 0302 clinical medicine, Inhibitory control, Reaction Time, Humans, Attention, Biological Psychiatry, Visual search, Middle Aged, 030227 psychiatry, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Inhibition, Psychological, Divided attention, Schizophrenia, Female, Schizophrenic Psychology, Psychology, 030217 neurology & neurosurgery, Diagnosis of schizophrenia, Cognitive psychology
Abstract

While the literature regarding the existence of difficulties in inhibition in schizophrenia is relatively consistent, it is not clear whether these difficulties reflect any specific deficit in an inhibitory control process or whether they are the result of deficits in the systems that regulate inhibitory control, such as attentional resources. This also raises the issue of attentional resources in schizophrenia, which offers a somewhat puzzling and sometimes contradictory picture. In this study, these issues were investigated by means of a paradigm in which the need for inhibitory control and the need for correct allocation of attentional resources varied parametrically. Twenty-six outpatients with a diagnosis of schizophrenia and 26 matched controls completed a visual search task during which distractors were presented and had to be inhibited. At the same time, they also completed an auditory target detection task of varying difficulty. The results show that the patients had difficulties both in inhibiting distractors and in correctly allocating attention to the two tasks. The results also show that these two difficulties were not related. This leads to the conclusion that schizophrenia involves both defective inhibitory control and faulty management of attentional resources, and that the former does not result from the latter. Furthermore, these effects seem to be neither dependent on processing speed, nor related to medication.

Published
2020

7. How do patients with Alzheimer's disease imagine their pain?

Author

Bernard Laurent, Jean-Claude Getenet, Julien Labouré, Céline Borg, Emilie Sala, Isabelle Rouch, Jean-Michel Dorey, Hanna Chainay, Chainay, Hanna, Laboratoire d'Etude des Mécanismes Cognitifs (EMC), and Université Lumière - Lyon 2 (UL2)

Subjects
Pain Threshold, medicine.medical_specialty, media_common.quotation_subject, Pain tolerance, Population, Pain, Disease, 03 medical and health sciences, [SCCO]Cognitive science, 0302 clinical medicine, Alzheimer Disease, medicine, Humans, Cognitive Dysfunction, 030212 general & internal medicine, education, ComputingMilieux_MISCELLANEOUS, media_common, Pain Measurement, education.field_of_study, business.industry, Cognition, Pain scale, [SCCO] Cognitive science, Pain management, Response bias, Anesthesiology and Pain Medicine, Feeling, Physical therapy, business, 030217 neurology & neurosurgery
Abstract

INTRODUCTION Pain is underdiagnosed and undertreated in patients with Alzheimer's disease (AD). Pain management is of major importance in this population to limit behavioural and functional consequences. Our study aimed to assess the capacity of AD patients to represent pain using a questionnaire exploring daily painful situations and to determine the most appropriate pain scale assessment. METHODS Twenty-eight patients with mild AD, 21 with moderate AD and 28 matched controls underwent the Situation Pain Questionnaire (SP-Q) and assessed imaginary pain with four pain scales. Two scores were compared between the three groups: the P(A) discrimination score and the response bias β score. P(A) reflects the degree of discrimination between high-pain and low-pain events, whereas the β score means the degree to which situations are considered as painful. RESULTS Our results showed that AD patients hardly discriminated the high- from low-pain events. Compared to controls, the mean P(A) score was significantly lower for Mild AD (p

Published
2020

8. Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia

Author

Anne-Lise Bohec, Marie-Françoise Suaud-Chagny, Jean-Michel Dorey, Thierry d'Amato, Ryad Tamouza, Romain Rey, Marion Leboyer, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - 'Neuropsychiatrie translationnelle' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CCSD, Accord Elsevier, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Adolescent, Synaptic pruning, [SDV]Life Sciences [q-bio], Immunology, Posterior parietal cortex, Prefrontal Cortex, 03 medical and health sciences, Behavioral Neuroscience, Superior temporal gyrus, 0302 clinical medicine, Parietal Lobe, Neuroplasticity, medicine, Humans, Temporal cortex, Complement component 4, Endocrine and Autonomic Systems, business.industry, Complement C4, Temporal Lobe, Dorsolateral prefrontal cortex, [SDV] Life Sciences [q-bio], 030104 developmental biology, medicine.anatomical_structure, Cerebral cortex, Schizophrenia, business, Neuroscience, 030217 neurology & neurosurgery
Abstract

Background In schizophrenia, abnormal synaptic pruning during adolescence may be due to altered expression of the Complement component 4 (C4). Overexpression of C4 genes has been identified in the total cerebral cortex and in 6 different brain regions of schizophrenic patients compared to controls. These alterations should be replicated and extended to other brain regions relevant to schizophrenia. Moreover, it remains unknown whether cerebral and peripheral C4 expression levels are related. Methods We explored C4 genes expression both at the cerebral and peripheral levels. Using shinyGEO application we analyzed C4 expression from eight Gene Expression Omnibus datasets obtained from 196 schizophrenic patients and 182 control subjects. First, we compared C4 expression between schizophrenic patients and controls in postmortem cerebral samples from 7 different brain regions. Then, we compared C4 expression between schizophrenic patients and controls in 4 peripheral tissues. Results At the cerebral level, we provide further evidence of C4 overexpression in schizophrenic patients. Consistently with a previous report, we found C4 overexpression in the dorsolateral prefrontal cortex and in the parietal cortex of schizophrenic patients. The observation of C4 overexpression was further extended to the superior temporal cortex and the associative striatum of schizophrenic patients. Conversely, no significant alteration of C4 expression was observed in peripheral tissues. Conclusions Our results support the hypothesis of an excessive Complement activity in various brain regions of schizophrenic patients which may disrupt the synaptic pruning process occurring during adolescence. C4 overexpression may be specific to the cerebral tissue while other alterations of the Complement system may be detected at the systemic level.

Published
2020

9. Impact of vascular risk factors on clinical outcome in elderly patients with depression receiving electroconvulsive therapy

Author

Jerome Brunelin, Filipe Galvao, Lucie Jurek, Mikail Nourredine, Jean-Michel Dorey, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre Hospitalier le Vinatier [Bron], Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CCSD, Accord Elsevier, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
medicine.medical_specialty, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Population, behavioral disciplines and activities, Late-life depression, 03 medical and health sciences, 0302 clinical medicine, Electroconvulsive therapy, Elderly, Rating scale, Risk Factors, Internal medicine, mental disorders, Medicine, Humans, Apathy, education, Electroconvulsive Therapy, Depression (differential diagnoses), Aged, Retrospective Studies, Psychiatric Status Rating Scales, education.field_of_study, Framingham Risk Score, business.industry, Depression, Beck Depression Inventory, ECT, Vascular risk-factor, Late life depression, 3. Good health, 030227 psychiatry, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Clinical Psychology, Treatment Outcome, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Background Although electroconvulsive therapy (ECT) is a highly effective, safe, and well-tolerated antidepressant treatment for late-life depression (LLD), there is large variability in response rates across individuals. We hypothesized that these variations would be in part explained by the level of vascular risk in this population. We therefore compared response rates to ECT in patients with LLD presenting with or without vascular risk factors (VRF). Methods 52 patients with LLD (age > 55) who received a course of ECT were separated into 2 groups according to the presence of VRF (n = 20) or not (n = 32). Framingham score (10-year risk for developing a coronary heart disease) was calculated for each patient. Our primary outcome was the number of responders to ECT in each group (defined as at least 50% decrease of the Montgomery–Asberg Depression Rating Scale score following ECT course). Scores at the self-rated Beck Depression Inventory are also reported. Results Patients with VRF presented significant lower response rates to ECT (12 out of 20; 60%) than patients without VRF (30 out of 32; 94%; p = 0.004). A negative correlation was found between Framingham score and changes in depression scores pre/post ECT (r = -0.42; p = 0.0039). Limitations Our study was limited by sample size and retrospective design. Conclusion Patients with LLD and VRF showed lower response rates to ECT than those without VRF. The more the VRF increased, the less the antidepressant effect of ECT was observed. Results are discussed in light of the role of apathy in clinical response to ECT.

Published
2020

10. Brain Volume Predicts Behavioral and Psychological Symptoms in Alzheimer’s Disease

Author

Isabelle Rouch, Catherine Padovan, Romain Bouet, Olivier Moreaud, Philippe Robert, Zaza Makaroff, Jean-Michel Dorey, Denis Federico, Nawele Boublay, Alzheimer’s Disease Neuroimaging Initiative, Marie-Odile Barrellon, Pierre Krolak-Salmon, Isabelle Gallice, Laboratoire de Psychologie et NeuroCognition (LPNC ), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), and Centre Hospitalier Universitaire [Grenoble] (CHU)

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Orbital gyri, Behavioral Symptoms, Neuropsychological Tests, Cohort Studies, 03 medical and health sciences, [SCCO]Cognitive science, 0302 clinical medicine, Physical medicine and rehabilitation, Neuroimaging, Alzheimer Disease, Predictive Value of Tests, medicine, Dementia, Humans, Cognitive Dysfunction, Longitudinal Studies, Prospective Studies, Prospective cohort study, Anterior cingulate cortex, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, business.industry, General Neuroscience, Brain, Cognition, General Medicine, medicine.disease, Mental Status and Dementia Tests, Magnetic Resonance Imaging, Frontal Lobe, Psychiatry and Mental health, Clinical Psychology, 030104 developmental biology, medicine.anatomical_structure, Frontal lobe, Brain size, Disease Progression, Female, Geriatrics and Gerontology, business, 030217 neurology & neurosurgery
Abstract

Background Behavioral and psychological symptoms of dementia (BPSD) are frequent and troublesome for patients and caregivers. Considering possible preventive approaches, a better understanding of underlying neural correlates of BPSD is crucial. Objective The aim is to assess whether brain regional volume predicts behavioral changes in mild AD. Methods This work took part from the PACO study, a multicenter and prospective study that included 252 patients with mild AD from 2009 to 2014. Fifty-three patients were retained. Forty healthy matched control subjects from the ADNI cohort were included as controls. Voxel-based morphometry analysis was conducted to assess regional brain volume using baseline MRI scans as a predictor of future behavioral changes over a period of 18 months. Behavior was assessed at baseline and longitudinally at 6-month intervals using the shortened form of the Neuropsychiatric Inventory (NPI). Results The volume of 23 brain structures in frontal, temporal, parietal, occipital, subcortical regions and cerebellum predicted the evolution of NPI scores. Frontal volume was the most powerful predictor with frontal gyri, anterior cingulate cortex, and orbital gyri being particularly involved. Conclusion To our knowledge, this is the first study assessing regional brain volumes as predictors of behavioral changes considered at earlier stages of AD. Up to 23 brain structures were associated with an increased risk of developing BPSD. Frontal lobe volume was the strongest predictor of future evolution of NPI. The involvement of multiple structures in the prediction of behavior suggests a role of the main large-scale networks involved in cognition.

Published
2020

11. Early and very early‐onset schizophrenia compared with adult‐onset schizophrenia: French FACE‐SZ database

Author

Romain Rey, Ophélia Godin, Pierre Vidailhet, Jasmina Mallet, Hélène Denizot, Christophe Lançon, Myrtille André, Isabelle Chereau, E. Bulzacka, Paul Roux, Marion Leboyer, Lore Brunel, Catherine Faget, N Coulon, David Misdrahi, George M. Anderson, Sylvain Leignier, Franck Schürhoff, Guillaume Fond, Fabrice Berna, Caroline Dubertret, Jean-Michel Dorey, Delphine Capdevielle, Christine Passerieux, Bruno Aouizerate, Julien Dubreucq, M. Andrianarisoa, Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Fondation FondaMental [Créteil], Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), CRC Scotland & London, Service de psychiatrie, CHU Clermont-Ferrand, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pôle de psychiatrie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-CHU Marseille, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Laboratoire de sciences cognitives et psycholinguistique (LSCP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance Publique-Hôpitaux de Marseille (AP-HM), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), École normale supérieure - Paris (ENS Paris), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris)

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Databases, Factual, Untreated psychosis, 050105 experimental psychology, early‐onset schizophrenia, lcsh:RC321-571, 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, very early‐onset schizophrenia, medicine, Humans, 0501 psychology and cognitive sciences, In patient, Age of Onset, Child, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Original Research, Psychiatric Status Rating Scales, Early onset schizophrenia, business.industry, 05 social sciences, Neuropsychology, medicine.disease, Prognosis, Very early onset, 3. Good health, Psychotic Disorders, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, symptomatology, dup, Female, Schizophrenic Psychology, France, business, duration of untreated psychosis, 030217 neurology & neurosurgery, adult‐onset schizophrenia
Abstract

Objective To compare the clinical symptomatology in patients with Early‐Onset Schizophrenia (EOS, N = 176), especially the subgroup Very Early Onset Schizophrenia (VEOS) and Adult Onset Schizophrenia (AOS, N = 551). Method In a large French multicentric sample, 727 stable schizophrenia patients, classified by age at onset of the disorder, were assessed using standardized and extensive clinical and neuropsychological batteries: AOS with onset ≥ 18 years and EOS with onset, To describe schizophrenia from childhood to adulthood is complex and patients with early‐onset schizophrenia (EOS) remain undiagnosed or misclassified, especially the subgroup with very early‐onset schizophrenia (VEOS). In patients with VEOS, the DUP which exceeds 8 years, almost eight times higher than in patients with AOS, objective the problem of early diagnosis and the need to develop diagnostic programs and management cares.

Published
2020

12. Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)

Author

C. Rabu, Wissam El-Hage, Isabel Nieto, Emmanuel Haffen, Antoine Yrondi, P. Courtet, Marion Leboyer, Franck Bellivier, Najib Allaïli, Guillaume Vaiva, Fanny Moliere, Jean-Michel Dorey, J.-B. Genty, Frédéric Haesebaert, Sylvie Lancrenon, Olivier Doumy, Djamila Bennabi, Laurent Schmitt, Florian Stephan, Bruno Aouizerate, Thierry Bougerol, C. Lançon, S. Destouches, Michel Walter, Raphaëlle Richieri, Thomas Charpeaud, J. Holtzmann, Pierre-Michel Llorca, M. Lefebvre, Vincent Camus, Centre d'expertise de la performance Gilles Cometti [Dijon] (CEP), Université de Bourgogne (UB), Sylia Stat Lancrenon S.A.S., Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Fondation FondaMental [Créteil], Clinique Psychiatrique Universitaire, Departement de Psychiatrie, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Deutsches Elektronen-Synchrotron [Zeuthen] (DESY), Helmholtz-Gemeinschaft, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), ERL 6230, Centre National de la Recherche Scientifique (CNRS), Helmholtz-Gemeinschaft = Helmholtz Association, Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), and Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, Psychopharmacology, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Comorbidity, Scientific evidence, 0302 clinical medicine, Elderly, lcsh:Psychiatry, 030212 general & internal medicine, Depression (differential diagnoses), ComputingMilieux_MISCELLANEOUS, Psychiatry, Anxiety disorders, Major depressive disorder, Pharmacotherapy, Substance use disorders, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 3. Good health, Neuropsychopharmacology, Psychiatry and Mental health, Practice Guidelines as Topic, Female, France, Biological psychiatry, Management of depression, Foundations, Research Article, medicine.medical_specialty, Substance-Related Disorders, lcsh:RC435-571, Personality Disorders, 03 medical and health sciences, medicine, Humans, Association (psychology), Expert Testimony, Biological Psychiatry, Aged, Depressive Disorder, Major, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, medicine.disease, Personality disorders, 030227 psychiatry, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Substance use, business
Abstract

International audience; Background Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking. Method The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments. Results The expert guidelines combine scientific evidence and expert clinician's opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression. Conclusion These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions.

Published
2019

13. One-Year Evolution of Behavioral and Psychological Symptoms of Dementia in Patients Initially Hospitalized in Cognitive Behavioral Units: The EVITAL Prospective Cohort

Author

Florence Fabre, Magalie Freulon, Isabelle Rouch, Nicolas Auguste, Christelle Mouchoux, Pierre Krolak-Salmon, Bernard Laurent, Sophie Jacqueline, Géraldine Martin-Gaujard, Elodie Pongan, Claire Sellier, Jean-Michel Dorey, Béatrice Trombert, and Denis Federico

Subjects
Male, medicine.medical_specialty, Psychosis, Longitudinal study, Clinical Dementia Rating, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, mental disorders, Humans, Medicine, Dementia, Longitudinal Studies, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Psychiatry, Aged, 80 and over, Psychotropic Drugs, business.industry, General Neuroscience, General Medicine, Mental Status and Dementia Tests, medicine.disease, Hospitalization, Psychiatry and Mental health, Clinical Psychology, Mood, Test score, Cohort, Disease Progression, Linear Models, Female, Geriatrics and Gerontology, Factor Analysis, Statistical, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

BACKGROUND The 2008-2012 French Alzheimer's Plan has provided hospital Cognitive and Behavioral Units (CBU) to improve the management of patients with productive behavioral and psychological symptoms of dementia (BPSD). Little is known concerning the behavioral outcome of these patients after discharge. OBJECTIVE The present study investigated the long-term evolution of BPSD over one year after CBU discharge. METHODS The EVITAL cohort included 221 participants admitted to the CBUs of 3 French hospitals. BPSD were collected using the Neuropsychiatric Inventory (NPI) at admission and 3, 6, and 12 months after hospitalization. The global NPI score evolution was assessed using a linear mixed-effect model. A four-factor model of the NPI including behavioral dyscontrol, psychosis, mood, and agitation subscores was also analyzed. RESULTS Our analysis focused on 148 patients followed up during 12 months and evaluated at each visit. The global NPI score was 48.5 (SD 21.7) at baseline, 28.8 (SD 18.7) at 3-month, 23.2 (SD 16.4) at 6-month and 20.9 (SD 15.9) at 12-month follow-up. The score significantly decreased from baseline to follow-up (F = 109.3 p

Published
2017

14. Personality Traits are Related to Selective Cognitive Impairment in Early Alzheimer's Disease

Author

Elodie Pongan, Isabelle Rouch, Bernard Laurent, Catherine Padovan, Pierre Krolak-Salmon, Jean-Michel Dorey, and Nawele Boublay

Subjects
0301 basic medicine, Male, media_common.quotation_subject, Human Characteristics, Prodromal Symptoms, Neuropsychological Tests, 03 medical and health sciences, 0302 clinical medicine, Cognition, Alzheimer Disease, Memory span, Personality, Humans, Cognitive Dysfunction, Cognitive skill, Big Five personality traits, media_common, Aged, Neuroticism, General Neuroscience, Prodromal Stage, General Medicine, Psychiatry and Mental health, Clinical Psychology, 030104 developmental biology, Cognitive Aging, Female, Geriatrics and Gerontology, Personality Assessment Inventory, Psychology, 030217 neurology & neurosurgery, Clinical psychology
Abstract

Background A link between personality traits and cognitive performance has been shown in normal adults and elderly individuals. Very few studies have evaluated this link in Alzheimer's disease (AD). Objective To better understand cognitive performance as regards to personality traits, our study was aimed to evaluate the role of premorbid personality on cognitive functioning in a population of patients presenting prodromal or mild AD. Methods 181 elderly with prodromal or mild AD participated in a cross-sectional, prospective cohort study. The participants completed a personality inventory and a neuropsychological battery exploring memory, attention, executive function, language, and praxis. Cognitive performance were compared according to the level of each personality trait, using multivariate MANOVA models. Results A higher level of neuroticism was associated with lower performance at similarities test (D = 9.49, p = 0.003), delayed Free and Cued Selective Reminding test (D = 5.22, p = 0.02), and digit span score (D = 7.99, p = 0.006). A higher level of openness was related to better performance at similarities (D = 4.33, p = 0.04), letter fluency (D = 11.45, p = 0.001), and category fluency test (D = 5.85, p = 0.02). Neuroticism interfered negatively with cognitive functioning at the prodromal stage; the association between openness and cognitive function was observed at both prodromal and mild AD stage. Conclusion These results suggest that personality traits, in particular neuroticism and openness, modulate cognitive abilities in patients with early AD. These results encourage the development of stress management programs to prevent its negative effects on cognitive aging.

Published
2019

15. Immediate Benefit of Art on Pain and Well-Being in Community-Dwelling Patients with Mild Alzheimer's

Author

Pierre Krolak-Salmon, Béatrice Trombert, Jean-Claude Getenet, Nicolas Auguste, Romain Bachelet, Bernard Laurent, Floriane Delphin-Combe, Jean-Michel Dorey, Barbara Tillmann, Elodie Pongan, Isabelle Rouch, Yohana Lévêque, Centre Mémoire de Ressources et de Recherche (CMRR Lyon), Hospices Civils de Lyon (HCL)-Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Laboratoire Parole et Langage (LPL), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] (LEAD), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Service de Santé Publique et d'Information Médicale, Psychiatrie, Centre Hospitalier le Vinatier [Bron], Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne] (CMRR 42), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), CHU Saint-Etienne, Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne Hôpital Nord], and CHU de Saint-Étienne Hôpital Nord [Saint Etienne]

Subjects
Gerontology, Male, Pain, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Alzheimer Disease, Intervention (counseling), medicine, Humans, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, Painting, business.industry, General Neuroscience, medicine.disease, humanities, Psychiatry and Mental health, Clinical Psychology, Well-being, Quality of Life, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Independent Living, Geriatrics and Gerontology, Alzheimer's disease, Singing, business, 030217 neurology & neurosurgery, Independent living, Art, Music
Abstract

Objective: The present report aims to evaluate whether singing intervention can bring an immediate benefit that is greater than the one provided by painting intervention on pain and well-being. Methods: Fifty-nine mild patients with Alzheimer disease were randomized to a 12-week singing (n = 31) or painting group (n = 28). In the present analysis, the immediate evolution of pain and well-being was compared across sessions between the 2 groups using mixed-effects models. Results: We observed a significant improvement in well-being for both singing and painting groups immediately after sessions, compared to the assessment before the sessions. We did not observe this improvement across the sessions for pain intensity measurement. Discussion: Our results revealed that both painting and singing interventions provide an immediate benefit on the patients’ well-being.

Published
2019

16. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental

Author

S. Destouches, Fanny Moliere, Sylvie Lancrenon, J. Holtzmann, Wissam El-Hage, Raphaëlle Richieri, Thomas Charpeaud, Bruno Aouizerate, Laurent Schmitt, Olivier Doumy, M. Lefebvre, Marion Leboyer, C. Lançon, N. Alaïli, Emmanuel Haffen, Michel Walter, C. Rabu, Isabel Nieto, Frédéric Haesebaert, Guillaume Vaiva, Thierry Bougerol, Djamila Bennabi, J.-B. Genty, P.-M. Llorca, Vincent Camus, Antoine Yrondi, Jean-Michel Dorey, P. Courtet, Franck Bellivier, Florian Stephan, Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Clermont-Ferrand, Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Fondation FondaMental [Créteil], Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Nutrition et Neurobiologie intégrée (NutriNeuro), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1 (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Université de Montpellier (UM), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Departement de Psychiatrie, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), El-Hage, Wissam, Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique

Subjects
Male, medicine.medical_specialty, Psychopharmacology, lcsh:RC435-571, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Resistance (psychoanalysis), Antidepressants, Expert consensus guidelines, Major depressive disorder, Pharmacotherapy, Treatment resistant depression, Scientific evidence, 03 medical and health sciences, Depressive Disorder, Treatment-Resistant, 0302 clinical medicine, lcsh:Psychiatry, medicine, Humans, 030212 general & internal medicine, Psychiatry, Association (psychology), Expert Testimony, Depression (differential diagnoses), Biological Psychiatry, Depressive Disorder, Major, medicine.disease, Antidepressive Agents, 3. Good health, 030227 psychiatry, Neuropsychopharmacology, Psychiatry and Mental health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Practice Guidelines as Topic, Female, France, Biological psychiatry, Psychology, Treatment-resistant depression, Research Article, Foundations
Abstract

Background Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established. Method Based on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of treatment-resistant depression. The expert guidelines combine scientific evidence and expert clinicians’ opinions to produce recommendations for treatment-resistant depression. A written survey comprising 118 questions related to highly-detailed clinical presentations was completed on a risk-benefit scale ranging from 0 to 9 by 36 psychiatrist experts in the field of major depression and its treatments. Key-recommendations are provided by the scientific committee after data analysis and interpretation of the results of the survey. Results The scope of these guidelines encompasses the assessment of pharmacological resistance and situations at risk of resistance, as well as the pharmacological and psychological strategies in major depression. Conclusion The expert consensus guidelines will contribute to facilitate treatment decisions for clinicians involved in the daily assessment and management of treatment-resistant depression across a number of common and complex clinical situations. Electronic supplementary material The online version of this article (10.1186/s12888-019-2237-x) contains supplementary material, which is available to authorized users.

Published
2019

17. Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence

Author

Caroline Dubertret, Franck Schürhoff, Joel Swendsen, Delphine Capdevielle, Marie de Pradier, Jean-Michel Dorey, F. Gabayet, Romain Rey, A. Schandrin, Jean-Marie Danion, Mathieu Urbach, Anne Marie Tronche, Christine Passerieux, Lore Brunel, Pierre-Michel Llorca, David Misdrahi, Raphaëlle Richieri, Arnaud Tessier, Isabelle Chereau, Guillaume Fond, Catherine Faget, Julien Dubreucq, and Fabrice Berna

Subjects
Adult, Male, Psychometrics, Population, Medication adherence, Comorbidity, Medication Adherence, 03 medical and health sciences, 0302 clinical medicine, Rating scale, Surveys and Questionnaires, Intervention (counseling), Humans, Medicine, In patient, education, Depression (differential diagnoses), education.field_of_study, Depression, business.industry, Electronic medical record, Reproducibility of Results, Middle Aged, medicine.disease, 3. Good health, 030227 psychiatry, Psychiatry and Mental health, Schizophrenia, Female, Self Report, business, 030217 neurology & neurosurgery, Clinical psychology
Abstract

OBJECTIVE: Medication nonadherence is one of the most important, and potentially modifiable, prognostic factors in the outcome of patients with schizophrenia. The aim of this article is to propose a new classification of adherence profiles according to the Medication Adherence Rating Scale (MARS) in a large community-dwelling sample of French patients with schizophrenia to provide a new tool to help clinicians in daily practice. METHODS: 319 community-dwelling patients from a national network of 10 Schizophrenia Expert Centers were interviewed between January 2009 and January 2014. Assessments were conducted with a dedicated electronic medical record including the Structured Clinical Interview for DSM-IV Disorders. A cluster analysis was performed to explore clinical variables associated with poor adherence. RESULTS: Two distinct groups of patients were identified relative to their main adherence style. Items about medications' subjective negative effects constituted the greatest discriminating factor between the 2 clusters. Patients with poor adherence (n = 117) were significantly younger (adjusted OR [aOR] = 1.036; 95% CI, 1.004-1.069) and had higher levels of current depression (aOR = 0.894; 95% CI, 0.829-0.964) and lower insight (aOR = 0.820; 95% CI, 0.693-0.970). CONCLUSIONS: The MARS provides a useful tool for clinicians and can also aid in the evaluation of adherence styles and their determinants in patients with schizophrenia. The element providing the greatest discriminative power between the 2 clusters was a subjective negative attitude toward medication. The findings also suggest that depression is more frequent in schizophrenia patients with poor adherence and that improving insight into illness might be suggested as a first-line intervention to improve adherence in this population.

Published
2016

18. Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset

Author

Mathieu Urbach, Isabelle Chereau, Dubreucq, Guillaume Fond, Lore Brunel, Bruno Aouizerate, P. Vidalhet, M. Favez, David Misdrahi, Christine Passerieux, Romain Rey, A. Schandrin, L. Boyer, C. Lançon, Delphine Capdevielle, A.M. Tronche, Fabrice Berna, H. Laouamri, Antoine Pelissolo, F. Schürhoff, Y. Le Strat, Jean-Michel Dorey, F. Gabayet, Pierre-Michel Llorca, Catherine Faget, Caroline Dubertret, Fondation FondaMental [Créteil], Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, and Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
medicine.medical_specialty, Cross-sectional study, medicine.medical_treatment, Schizoaffective disorder, Violence, Antipsychotic, 03 medical and health sciences, Aggressiveness, 0302 clinical medicine, medicine, Young adult, Psychiatry, Pharmacology, Benzodiazepine, biology, Buss perry scale, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, medicine.disease, biology.organism_classification, 3. Good health, 030227 psychiatry, Mood, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Cannabis, Psychology, 030217 neurology & neurosurgery, Clinical psychology, Cohort study
Abstract

International audience; INTRODUCTION:The primary objective of this study was to determine if second-generation antipsychotic (SGA) administration was associated with lower aggressiveness scores compared to first-generation (FGA) in schizophrenia (SZ). The secondary objective was to determine if antidepressants, mood stabilizers, and benzodiazepines administration were respectively associated with lower aggressiveness scores compared to patients who were not administered these medications.METHODS:Three hundred thirty-one patients with schizophrenia (N = 255) or schizoaffective disorder (N = 76) (mean age = 32.5 years, 75.5 % male gender) were systematically included in the network of FondaMental Expert Center for Schizophrenia and assessed with the structured clinical interview for DSM-IV Axis I disorders and validated scales for psychotic symptomatology, insight, and compliance. Aggressiveness was measured by the Buss-Perry Aggression Questionnaire (BPAQ) score. Ongoing psychotropic treatment was recorded.RESULTS:Patients who received SGA had lower BPAQ scores than patients who did not (p = 0.01). More specifically, these patients had lower physical and verbal aggression scores. On the contrary, patients who received benzodiazepines had higher BPAQ scores than patients who did not (p = 0.04). No significant difference was found between BPAQ scores of patients respectively being administered mood stabilizers (including valproate), antidepressant, and the patients who were not. These results were found independently of socio-demographical variables, psychotic symptomatology, insight, compliance into treatment, daily-administered antipsychotic dose, the way of antipsychotic administration (oral vs long acting), current alcohol disorder, and daily cannabis consumption.CONCLUSION:The results of the present study are in favor of the choice of SGA in SZ patients with aggressiveness, but these results need further investigation in longitudinal studies. Given the potent side effects of benzodiazepines (especially dependency and cognitive impairment) and the results of the present study, their long-term prescription is not recommended in patients with schizophrenia and aggressive behavior.

Published
2015

19. Personality Modulates the Efficacy of Art Intervention on Chronic Pain in a Population of Patients with Alzheimer's Disease

Author

Isabelle Rouch, Yohana Lévêque, Bernard Laurent, Nicolas Auguste, Barbara Tillmann, Pierre Krolak-Salmon, Jean Claude Getenet, Elodie Pongan, Béatrice Trombert, Jean-Michel Dorey, Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne] (CMRR 42), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Laboratoire Parole et Langage (LPL), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] (LEAD), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Service de Santé Publique et d'Information Médicale, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Psychiatrie, Centre Hospitalier le Vinatier [Bron], Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne Hôpital Nord], CHU de Saint-Étienne Hôpital Nord [Saint Etienne], Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB), CHU Saint-Etienne, and Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, media_common.quotation_subject, [SDV]Life Sciences [q-bio], Population, law.invention, Group psychotherapy, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Alzheimer Disease, Medicine, Personality, Humans, 030212 general & internal medicine, Big Five personality traits, Brief Pain Inventory, education, ComputingMilieux_MISCELLANEOUS, media_common, Aged, education.field_of_study, business.industry, General Neuroscience, Chronic pain, Art Therapy, General Medicine, medicine.disease, Neuroticism, humanities, 3. Good health, Psychiatry and Mental health, Clinical Psychology, Physical therapy, Psychotherapy, Group, Female, Geriatrics and Gerontology, Chronic Pain, business, 030217 neurology & neurosurgery
Abstract

Background Alzheimer's disease (AD) mainly occurs in elderly individuals. Comorbidities and chronic pain are frequent in this population. Previous studies revealed that personality modulates both chronic pain (CP) andADoccurrence and evolution. Moreover, as pain treatments can induce side-effects, non-drugs treatments, such as art interventions, are interesting alternative therapies for decreasing CP in these patients. Objective Our aim was to assess the potential role of personality traits on art intervention efficacy for reducing CP in a population of patients with mild AD. Methods Design: multicenter randomized controlled trial. Fifty mild AD patients underwent a 12-week art intervention including singing and painting groups. Personality was assessed with the Big Five Inventory before the sessions. CP was measured with Numeric Rating Scale (NRS) [Usual pain (NRS-U) and most Intense pain (NRS-I)], Simple Visual Scale [Usual pain (SVS-U) and most Intense pain (SVS-I)] and Brief Pain Inventory (BPI) before and after the sessions. The influence of personality traits on CP evolution before and after art intervention was assessed with multiple linear regression models. Results A positive association was observed between neuroticism and the evolution of three CP measures including NRS-U (B = 0.34, p = 0.01), SVS-U (B = 0.20, p = 0.04), and BPI-U (B = 0.46, p = 0.02) evolution. No significant relationship was observed between neuroticism and NRS-I, SVS-I and BPI-R evolution. Conclusions Our findings suggest that neuroticism can decrease the efficacy of group art intervention on pain in patients with mild AD. Individual therapies could be more appropriate for these patients. These results emphasize the interest of taking into account patients' personality before proposing them to participate to a group therapy.

Published
2018

20. Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset

Author

Guillaume Fond, Marion Leboyer, Catherine Faget, Mathieu Urbach, Karine Chevreul, Romain Rey, C. Lançon, Pierre Vidailhet, F. Schürhoff, Jean-Michel Dorey, David Misdrahi, I. Chereau-Boudet, Delphine Capdevielle, Bruno Aouizerate, Sylvain Leigner, Julien Dubreucq, Myrtille André, Jasmina Mallet, Paul Roux, Pierre-Michel Llorca, Caroline Dubertret, Fabrice Berna, Amélie Prigent, Alice Plas, Charles Laidi, Service NEUROSPIN (NEUROSPIN), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Fondation FondaMental [Créteil], Pôle de Psychiatrie [Hôpital Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital H. Mondor - A. Chenevier, Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris]-Université Paris Diderot - Paris 7 (UPD7), Hôtel-Dieu, Département de psychiatrie adulte, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital La Colombière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital H. Mondor - A. Chenevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Cross-sectional study, Cost, Schizophrenia (object-oriented programming), [SDV]Life Sciences [q-bio], Psychological intervention, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Cost of Illness, Health care, Medicine, Humans, Schizophernia, Pharmacology (medical), 030212 general & internal medicine, Cognitive rehabilitation therapy, Psychiatry, Socioeconomic status, Biological Psychiatry, health care economics and organizations, Pharmacology, business.industry, Medico-economic, Health Care Costs, Middle Aged, 030227 psychiatry, 3. Good health, Hospitalization, Psychiatry and Mental health, Cross-Sectional Studies, Neurology, Cohort, Schizophrenia, Female, Neurology (clinical), France, business, Cohort study
Abstract

International audience; INTRODUCTION: There is a lack of data on health care consumption of patients suffering from schizophrenia, as well as on the related health care costs. Factors associated with health care costs have not been widely studied, whereas knowledge on this topic would allow identifying risk factors and delineating strategies to improve patients' health and follow-up, likely to also decrease health care costs. The aim of this study was to estimate the average direct health care cost of patients with schizophrenia in France and to identify the factors associated with this cost. METHODS: The study population included patients with schizophrenia enrolled in the FondaMental Advanced Centers of Expertise for Schizophrenia cohort. We accounted for the costs directly related to the treatment of schizophrenia. They included the costs of hospitalizations (full- and part-time), psychiatric ambulatory consultations and medications. We studied three categories of factors potentially associated with direct health care costs: demographic, socioeconomic and clinical characteristics. RESULTS: Three hundred and ninety five patients with schizophrenia were included. The mean (median) annual direct health care cost per patient amounted to \texteuro14,995 (\texteuro3,435). A lower level of functioning and being single were associated with a higher cost. A significant association between the expert center of inclusion and the direct health care cost of schizophrenia was also highlighted. CONCLUSION: Our results highlighted the significant cost of schizophrenia and suggest that improvement in patient care, based on well-validated targeted therapeutic interventions such as psycho-education and cognitive rehabilitation, could reduce worsening in symptom severity and therefore decrease health care costs.

Published
2018

21. Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort

Author

David Misdrahi, Sylvain Leignier, Fabrice Berna, Laurent Boyer, Guillaume Fond, M. Andrianarisoa, Myrtille André, Romain Rey, Ophélia Godin, Bruno Aouizerate, Julien Dubreucq, Pierre Vidailhet, F. Schürhoff, Delphine Capdevielle, Marion Leboyer, Dominique Costagliola, Christine Passerieux, Isabelle Chereau, Jean-Michel Dorey, Pierre-Michel Llorca, Caroline Dubertret, Paul Roux, Jasmina Mallet, Christophe Lançon, and Catherine Faget

Subjects
Adult, Pediatrics, medicine.medical_specialty, Psychosis, Population, Severity of Illness Index, Medication Adherence, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Recurrence, Risk Factors, Severity of illness, medicine, Humans, Longitudinal Studies, education, Metabolic Syndrome, education.field_of_study, business.industry, Case-control study, Odds ratio, medicine.disease, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, Logistic Models, Schizophrenia, Case-Control Studies, Cohort, France, business, 030217 neurology & neurosurgery, Diagnosis of schizophrenia, Antipsychotic Agents
Abstract

Objective Predicting relapse is a major challenge in schizophrenia from a clinical and medico-economic point of view. During recent decades, major psychiatric disorders have been found to be extensively associated with metabolic disorders, even before the illness onset, with a prevalence estimated to be 35% in this population. However, no study to date has, to our knowledge, explored the potential impact of metabolic syndrome (MetS) on relapse. Methods From 2010 to 2016, 185 patients (mean age = 32 years) with a DSM-IV-TR diagnosis of schizophrenia were included in the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) cohort and followed up for 1 year. Multivariable logistic regression was performed to estimate the adjusted odds ratio for relapse. Results Thirty-seven percent of stabilized outpatients with schizophrenia (mean illness duration = 11 years) experienced a relapse at least once during the 1 year of follow-up. MetS strongly predicted relapse at 1 year, independently of illness severity, insight into illness, and treatment characteristics (including medication compliance). Patients with MetS at baseline had a 3 times higher risk (95% CI, 1.1-8.4) of experiencing a new episode of psychosis during the 12 months of follow-up. Conclusions Further studies should determine if reducing or preventing MetS could help to protect subjects with schizophrenia from relapse.

Published
2017

22. Predictors of Discharge Destinations and Three-Month Evolution of Patients Initially Hospitalized in a Cognitive Behavioral Unit

Author

Isabelle Rouch, Denis Federico, Pierre Krolak-Salmon, Béatrice Trombert-Paviot, Jean-Michel Dorey, Claire Sellier, Elodie Pongan, Bernard Laurent, Florence Fabre, and Nicolas Auguste

Subjects
Male, medicine.medical_specialty, Patient Readmission, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Sex Factors, Quality of life, Risk Factors, Internal medicine, medicine, Dementia, Humans, Prospective Studies, Aged, Aged, 80 and over, 030214 geriatrics, Cognitive Behavioral Therapy, Marital Status, business.industry, General Neuroscience, Institutionalization, Cognition, General Medicine, medicine.disease, Prognosis, Patient Discharge, Nursing Homes, Psychiatry and Mental health, Clinical Psychology, Caregivers, Spouse, Disease Progression, Quality of Life, Marital status, Population study, Female, Geriatrics and Gerontology, business, Nursing homes, 030217 neurology & neurosurgery
Abstract

BACKGROUND Previous studies showed that a third of patients living at home entered an institution after hospitalization in Cognitive and Behavioral Units (CBUs). OBJECTIVE The main objective of this study was to identify predictors of discharge destination for these patients. The secondary objective was to estimate whether institutionalization can have an impact on a patient's long-term prognosis. METHODS The study population was selected from the EVITAL study and included 140 participants living at home before hospitalization in CBUs. Factors favoring nursing-home admission were investigated and the impact of discharge destinations (i.e., home or nursing home) on patients' prognosis was examined. RESULTS Institutionalized patients were more likely to be women (F = 4.7; p = 0.03), with a higher dementia severity (F = 9.82; p = 0.007), often living alone (F = 19.69; p = 0.001), with a caregiver other than spouse (F = 8.93; p = 0.003), and with a higher patient quality of life (QoL) according to the caregiver (F = 11.73; p = 0.001). When using multivariate logistic linear regressions, we showed a relationship between marital status (OR = 0.19, 95% CI: 0.08-0.43, p

Published
2017

23. Can Musical or Painting Interventions Improve Chronic Pain, Mood, Quality of Life, and Cognition in Patients with Mild Alzheimer's Disease? Evidence from a Randomized Controlled Trial

Author

Elodie, Pongan, Barbara, Tillmann, Yohana, Leveque, Béatrice, Trombert, Jean Claude, Getenet, Nicolas, Auguste, Virginie, Dauphinot, Hanane, El Haouari, Malou, Navez, Jean-Michel, Dorey, Pierre, Krolak-Salmon, Bernard, Laurent, Isabelle, Rouch, and Elodie, Vulliez

Subjects
Male, medicine.medical_specialty, law.invention, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Randomized controlled trial, law, Alzheimer Disease, medicine, Memory span, Humans, Single-Blind Method, 030212 general & internal medicine, Aged, Aged, 80 and over, Mood Disorders, General Neuroscience, Chronic pain, Art Therapy, General Medicine, medicine.disease, Psychiatry and Mental health, Clinical Psychology, Mood, Treatment Outcome, Mood disorders, Physical therapy, Linear Models, Quality of Life, Anxiety, Female, Paintings, Geriatrics and Gerontology, Verbal memory, medicine.symptom, Chronic Pain, Psychology, Cognition Disorders, 030217 neurology & neurosurgery, Music, Clinical psychology, Follow-Up Studies
Abstract

BACKGROUND Among non-pharmacological therapies, musical intervention is often used for patients with Alzheimer's disease (AD) and patients presenting chronic pain. However, their efficacy is still under debate. OBJECTIVE Our aim was to determine the efficacy of choral singing versus painting sessions on chronic pain, mood, quality of life, and cognition in AD patients. METHODS In this multicenter randomized controlled trial, 59 mild AD patients were randomized to a 12-week singing (SG; n = 31) or painting group (PG; n = 28). Chronic pain, anxiety, depression, and quality of life were assessed before, after, and 1 month after the sessions. Cognitive abilities were assessed before and after interventions. The evolution of these different measures was assessed with mixed linear models. The primary data analysis was by intention-to-treat, and completed by a 'per protocol' approach. RESULTS Both singing and painting interventions led to significant pain reduction (Time effect: F = 4.71; p = 0.01), reduced anxiety (Time effect: F = 10.74; p

Published
2017

24. From Diogenes syndrome to Asperger's syndrome?

Author

Jean-Michel Dorey, Catherine Padovan, Isabelle Rouch, Mathilde Bonze, and Mathieu Herrmann

Subjects
03 medical and health sciences, Psychiatry and Mental health, medicine.medical_specialty, 0302 clinical medicine, S syndrome, Diogenes syndrome, business.industry, medicine, Geriatrics and Gerontology, medicine.disease, Psychiatry, business, 030227 psychiatry
Published
2017

25. Mediation Analyses of Insight, Quality of Life, Depression, and Suicidality: Results From the FACE-SZ Cohort

Author

Raphaëlle Richieri, Jean-Michel Dorey, F. Gabayet, Delphine Capdevielle, Christine Passerieux, Bruno Aouizerate, A. Schandrin, Julien Dubreucq, Isabelle Chereau, Franck Schürhoff, Catherine Faget-Agius, Lore Brunel, Pierre Vidailhet, Jasmina Mallet, Pierre-Michel Llorca, Arnaud Tessier, Romain Rey, S. Fonteneau, Fabrice Berna, Caroline Dubertret, Paul Roux, Mathieu Urbach, and David Misdrahi

Subjects
Adult, Male, Mediation (statistics), Suicidal Ideation, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Quality of life, Risk Factors, Medicine, Humans, Risk factor, Suicidal ideation, Depression (differential diagnoses), Depressive Disorder, Models, Statistical, business.industry, Awareness, Middle Aged, medicine.disease, 030227 psychiatry, Psychiatry and Mental health, Cross-Sectional Studies, Psychotic Disorders, Schizophrenia, Cohort, Quality of Life, Female, medicine.symptom, business, 030217 neurology & neurosurgery, Clinical psychology, Cohort study
Abstract

Objective: The relationship between greater insight and increased risk of suicide in patients with schizophrenia is debated. The purpose of this study was to assess whether quality of life (QoL) and depression mediated the association between insight and suicidality. Methods: Between March 2010 and December 2015, 527 community-dwelling adults with stable schizophrenia according to DSM-IVcriteria were included in a multicenter cross-sectional study, the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Structural equation modeling was used for mediation analyses among insight, QoL, depression, and suicidality, controlling for the global level of schizophrenic symptoms. Results: The model provided a good fit for the data ( (chi 3 2 =1.4, P = .708, Tucker-Lewis index = 1, comparative fit index =1, root mean square error of approximation =0, standardized root mean square residual =0.008) and explained 27% of the variance in suicidality. Poorer QoL and greater severity of depression mediated 68.4% of the positive association between insight and suicidality (full mediation). Poorer QoL mediated 48% of the positive effect of insight on depression (partial mediation). The severity of depression mediated 91.2% of the negative relationship between QoL and suicidality (full mediation). Conclusions: Insight appears to be an indirect risk factor for suicide in patients with schizophrenia, with the link being mediated by poorer QoL and worse underlying depression, mainly by a sequential pathway but also by a less important parallel pathway.

Published
2017

26. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set

Author

Christine Passerieux, A. Schandrin, Lore Brunel, E. Bulzacka, Catherine Faget, A.M. Tronche, P. Vidalhet, Franck Schürhoff, Bruno Aouizerate, Isabelle Chereau, Guillaume Fond, Y. Le Strat, Raphaëlle Richieri, Jean-Michel Dorey, Jean-Arthur Micoulaud-Franchi, F. Gabayet, Julien Dubreucq, Delphine Capdevielle, Mathieu Urbach, Pierre-Michel Llorca, Romain Rey, Ophélia Godin, Marion Leboyer, Fabrice Berna, Caroline Dubertret, David Misdrahi, United Monolithic Semiconductors (UMS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Fondation FondaMental [Créteil], Université Montpellier 1 (UM1), INSERM U-888, Institut National de la Santé et de la Recherche Médicale (INSERM), Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Laboratoire de Neurosciences Cognitives [Marseille] (LNC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), ONERA - The French Aerospace Lab [Toulouse], ONERA, Departement de Psychiatrie, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants (SPMC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), and Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)

Subjects
Adult, Male, medicine.medical_specialty, [SHS.PSY]Humanities and Social Sciences/Psychology, Comorbidity, Body Mass Index, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Prevalence, Humans, Abdominal obesity, Depression (differential diagnoses), 2. Zero hunger, Hypertriglyceridemia, Inflammation, Metabolic Syndrome, Psychiatric Status Rating Scales, Depressive Disorder, Major, Odds ratio, medicine.disease, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Quality, Antidepressive Agents, 3. Good health, 030227 psychiatry, Diagnostic and Statistical Manual of Mental Disorders, Psychiatry and Mental health, Clinical Psychology, Endocrinology, C-Reactive Protein, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, medicine.symptom, Age of onset, Metabolic syndrome, Waist Circumference, Psychology, Body mass index, 030217 neurology & neurosurgery, Biomarkers
Abstract

International audience; Objectives: The relation between C-Reactive Protein (CRP), depression ă and antidepressant consumption has been well explored in major ă depressive disorders but not in schizophrenia, which has a high rate of ă depression comorbidity. The objectives of this study were: (i) to ă determine the prevalence of abnormal CRP levels, depression and ă antidepressant consumption in a multicenter community-dwelling sample of ă subjects with schizophrenia (ii) to determine the association between ă abnormal CRP levels, depression and antidepressant consumption in ă schizophrenia. ă Method: 219 stable patients with schizophrenia (mean age=31.6 years, ă 75.3% male gender) were systematically included in the multicentre ă network of FondaMental Expert Center for schizophrenia (FACESZ) and ă assessed with a dedicated electronic medical record including the ă Structured Clinical Interview for DSM-IV Axis I Disorders and Calgary ă Depression Scale for depression. High sensitivity CRP (hs-CRP) was ă measured with an assay using nephelometry (Dade Behring). Abnormal CRP ă level was defined by levels > 3 mg/L. Current medication was recorded. ă Results: Overall, 63 subjects (28.8%) were found to have abnormal CRP ă levels, 43 (20.1%) received a diagnosis of comorbid current depression, ă and 51 (31.9%) had ongoing antidepressant treatment. In univariate ă analysis, abnormal CRP levels were found to be significantly associated ă with body mass index (BMI) (p < 0.0001), hypertriglyceridemia (p ă =0.0015), high waist circumference (p < 0.0001), metabolic syndrome (p= ă 0.0011), abdominal obesity (p < 0.0001) and with antidepressant ă consumption (p= 0.01), while depression, psychotic symptomatology, age ă of onset, illness duration, sociodemographic characteristics, current ă tobacco or cannabis status, hypertension or high fasting glucose were ă not (all p > 0.05). ă In a multivariate model, abnormal CRP was associated with antidepressant ă consumption independently of other confounding variables (adjusted Odds ă Ratio =2.8, 95% confidence interval 1.226.62). Metabolic syndrome was ă also independently associated with abnormal CRP (adjusted Odds Ratio = ă 2.6, 95% confidence interval 1.01-6.71). ă Conclusion: Abnormal CRP levels in schizophrenia were found to be ă associated with antidepressant consumption, but not with depression. The ă potential mechanisms were discussed. Antidepressant consumption should ă be systematically recorded in future studies exploring inflammation in ă schizophrenia. Future clinical trials of interventions directed at ă lowering the level of CRP and other inflammatory markers are discussed. ă (c) 2015 Elsevier BY. All rights reserved.

Published
2015

27. Development of the Alcohol Quality of Life Scale (AQoLS): a new patient-reported outcome measure to assess health-related quality of life in alcohol use disorder

Author

Pierre-Michel Llorca, Lynn Owens, Bruno Falissard, P. Laramée, Diane Whalley, Henri-Jean Aubin, N. Hawken, Mark Price, Lynda C. Doward, Jean-Michel Dorey, S.R. Crawford, Amandine Luquiens, Centre Hospitalier le Vinatier [Bron], Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Santé mentale et santé publique (SMSP - U1178), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Laboratoire d'Electronique et des Technologies de l'Information (CEA-LETI), and Université Grenoble Alpes (UGA)-Direction de Recherche Technologique (CEA) (DRT (CEA))

Subjects
Adult, Male, Psychometrics, Health Status, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Psychological intervention, Poison control, Alcohol use disorder, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Surveys and Questionnaires, Content validity, Humans, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Aged, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, Debriefing, [SCCO.NEUR]Cognitive science/Neuroscience, Public Health, Environmental and Occupational Health, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Focus Groups, Middle Aged, medicine.disease, United Kingdom, 3. Good health, Patient Outcome Assessment, Alcoholism, Quality of Life, Female, Patient-reported outcome, France, Self Report, Medical emergency, Thematic analysis, business, 030217 neurology & neurosurgery, Clinical psychology
Abstract

The development of patient-centred approaches and of reduction in consumption strategies in alcohol use disorder requires giving a larger place to qualitative assessments that are closer to patients’ concerns and more clinically relevant than drinking outcomes and generic health-related quality of life instrument. Our purpose was to develop from patients input the Alcohol Quality of Life Scale (AQoLS), a disease-specific measure for alcohol use disorder (AUD). Concept elicitation focus groups were conducted with AUD patients in the UK and France. Thematic analysis was used to identify key areas of impact of AUD, and draft items were developed to capture these issues. The draft items underwent expert review to ensure clinical and cross-cultural applicability. Two iterative rounds of cognitive debriefing interviews were conducted with AUD patients in both countries, to assess face and content validity. From focus groups conducted with 38 AUD patients, seven areas of impact emerged, forming the basis for the AQoLS: relationships, activities, looking after self, emotional impact, control, living conditions, and sleep. An initial pool of 90 items was reduced to 50 following the review process. In cognitive interviews, the measure took less than 10 min to complete, and patients reported that items were relevant to their experience. Following Round 1 interviews (n = 16), 14 items were removed because patients felt they were unclear or uneasy to respond to, 2 were combined, 7 were revised, and 4 new items were added. The recall period of 2 weeks was changed to 4 weeks, based on patient comments. Following Round 2 interviews (n = 15), 5 items were removed and 3 were modified to produce the 34-item AQoLS. As the only de novo measure of health-related quality of life developed specifically for AUD, the AQoLS offers the potential of increased sensitivity to show the effectiveness of therapeutic interventions from the patient’s perspective.

Published
2015

28. Neuroanatomical Correlates of Recognizing Face Expressions in Mild Stages of Alzheimer’s Disease

Author

Catherine Padovan, Alexander Hammers, Alzheimer’s Disease Neuroimaging Initiative, Rolf A. Heckemann, Jean-Michel Dorey, Isabelle Rouch, Nawele Boublay, Laurie-Anne Sapey-Triomphe, Marie-Anne Hénaff, and Pierre Krolak-Salmon

Subjects
Male, medicine.medical_specialty, Emotion classification, media_common.quotation_subject, lcsh:Medicine, Neuropsychological Tests, Audiology, Anger, Biology, 03 medical and health sciences, 0302 clinical medicine, Alzheimer Disease, Image Processing, Computer-Assisted, medicine, Humans, lcsh:Science, Aged, 030304 developmental biology, media_common, Aged, 80 and over, 0303 health sciences, Facial expression, Multidisciplinary, Fusiform gyrus, lcsh:R, Brain, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Disgust, Neuroanatomy, medicine.anatomical_structure, Pattern Recognition, Visual, Case-Control Studies, Brain size, Female, lcsh:Q, Alzheimer's disease, Facial Recognition, 030217 neurology & neurosurgery, Research Article
Abstract

Early Alzheimer's disease can involve social disinvestment, possibly as a consequence of impairment of nonverbal communication skills. This study explores whether patients with Alzheimer's disease at the mild cognitive impairment or mild dementia stage have impaired recognition of emotions in facial expressions, and describes neuroanatomical correlates of emotion processing impairment. As part of the ongoing PACO study (personality, Alzheimer's disease and behaviour), 39 patients with Alzheimer's disease at the mild cognitive impairment or mild dementia stage and 39 matched controls completed tests involving discrimination of four basic emotions-happiness, fear, anger, and disgust-on photographs of faces. In patients, automatic volumetry of 83 brain regions was performed on structural magnetic resonance images using MAPER (multi-atlas propagation with enhanced registration). From the literature, we identified for each of the four basic emotions one brain region thought to be primarily associated with the function of recognizing that emotion. We hypothesized that the volume of each of these regions would be correlated with subjects' performance in recognizing the associated emotion. Patients showed deficits of basic emotion recognition, and these impairments were correlated with the volumes of the expected regions of interest. Unexpectedly, most of these correlations were negative: better emotional facial recognition was associated with lower brain volume. In particular, recognition of fear was negatively correlated with the volume of amygdala, disgust with pallidum, and happiness with fusiform gyrus. Recognition impairment in mild stages of Alzheimer's disease for a given emotion was thus associated with less visible atrophy of functionally responsible brain structures within the patient group. Possible explanations for this counterintuitive result include neuroinflammation, regional β-amyloid deposition, or transient overcompensation during early stages of Alzheimer's disease.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results